An information-intensive approach to the molecular pharmacology of cancer

…, JK Buolamwini, WW Van Osdol, AP Monks… - Science, 1997 - science.org
Since 1990, the National Cancer Institute (NCI) has screened more than 60,000 compounds
against a panel of 60 human cancer cell lines. The 50-percent growth-inhibitory …

New colorimetric cytotoxicity assay for anticancer-drug screening

…, R Storeng, D Scudiero, A Monks… - JNCI: Journal of the …, 1990 - academic.oup.com
We have developed a rapid, sensitive, and inexpensive method for measuring the cellular
protein content of adherent and suspension cultures in 96-well microtiter plates. The method …

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm

…, RH Shoemaker, L Hodes, A Monks… - JNCI: Journal of the …, 1989 - academic.oup.com
The objective of this study was to develop and investigate an approach to optimally detect,
rank, display, and analyze patterns of differential growth inhibition among cultured cell lines. …

Characterization of the p53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations with the Growth …

…, TG Myers, S Fan, M Mutoh, DA Scudiero, A Monks… - Cancer research, 1997 - AACR
In the present study, we report the characterization of the p53 tumor suppressor pathway in
the 60 cell lines of the National Cancer Institute (NCI) anticancer drug screen, as well as …

Metrics for radiologists in the era of value-based health care delivery

A Sarwar, G Boland, A Monks, JB Kruskal - Radiographics, 2015 - pubs.rsna.org
Accelerated by the Patient Protection and Affordable Care Act of 2010, health care delivery
in the United States is poised to move from a model that rewards the volume of services …

Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias

…, S Kitada, DA Scudiero, G Tudor, YH Qui, A Monks… - Clinical Cancer …, 2000 - AACR
Expression of several inhibitor of apoptosis proteins (IAPs) was investigated in the National
Cancer Institute panel of 60 human tumor cell lines, and the expression and prognostic …

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

A Monks, D Scudiero, P Skehan… - JNCI: Journal of the …, 1991 - academic.oup.com
We describe here the development and implementation of a pilot-scale, in vitro, anticancer
drug screen utilizing a panel of 60 human tumor cell lines organized into subpanels …

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay

MC Alley, DA Scudiero, A Monks, ML Hursey… - Cancer research, 1988 - AACR
For the past 30 years strategies for the preclinical discovery and development of potential
anticancer agents have been based largely upon the testing of agents in mice bearing …

Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines

DA Scudiero, RH Shoemaker, KD Paull, A Monks… - Cancer research, 1988 - AACR
We have previously described the application of an automated microculture tetrazolium
assay (MTA) involving dimethyl sulfoxide solubilization of cellular-generated 3-(4,5-…

[HTML][HTML] Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

…, LM Wahl, ED Harris, JA Mikovits, AP Monks… - Genome biology, 2001 - Springer
Background Flavopiridol, a flavonoid currently in cancer clinical trials, inhibits cyclin-dependent
kinases (CDKs) by competitively blocking their ATP-binding pocket. However, the …